Nicolette Owens
Family · Phoenix, AZNPI 1346914512
Payments from drug & device makers
Across 405 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$863
- GSK$595
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$419
- Lilly USA, LLC$419
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,532100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,336 |
| AstraZeneca | 21 | $1,104 |
| Novo Nordisk | 56 | $863 |
| GSK | 36 | $595 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $419 |
| Lilly USA, LLC | 33 | $419 |
| Pfizer | 22 | $380 |
| Amgen | 16 | $356 |
| Sumitomo Pharma America, Inc. | 9 | $241 |
| Boehringer Ingelheim | 11 | $213 |
| Astellas Pharma US Inc | 9 | $183 |
| Bayer | 11 | $165 |
| Eisai Inc. | 6 | $144 |
| Abbott | 5 | $111 |
| Aimmune Therapeutics, Inc. | 5 | $104 |
| Corcept Therapeutics | 4 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Medtronic | 2 | $67 |
| Novartis | 3 | $66 |
| Exact Sciences | 4 | $66 |
| Impel Pharmaceuticals Inc. | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Phadia US Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Merck | 1 | $30 |
| Mylan Specialty L.p. | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Boston Scientific | 1 | $26 |
| Johnson & Johnson | 1 | $24 |
| Tonix Medicines, Inc. | 1 | $23 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Abiomed | 1 | $20 |
| Tolmar, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,534 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $57,917 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $47,589 |
| OzempicSemaglutide | 23 | $47,335 |
| FarxigaDapagliflozin Propanediol | 24 | $37,720 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,025 |
| RybelsusSemaglutide | 18 | $23,155 |
| JardianceEmpagliflozin | 16 | $22,689 |
| VraylarCariprazine Hcl | 14 | $22,618 |
| TrulicityDulaglutide | 15 | $19,250 |
| LinzessLinaclotide | 11 | $16,937 |
| MyrbetriqMirabegron | 21 | $15,363 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,904 |
| Gabapentin | 81 | $2,660 |
| Atorvastatin Calcium | 188 | $2,600 |
| Omeprazole | 117 | $2,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $863 | $70,49041 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,104 | $65,74562 claims |
| PfizerEliquis | $380 | $57,91740 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $595 | $56,49363 claims |
| AbbVieVraylar, Linzess | $1,336 | $39,55525 claims |
| Boehringer IngelheimJardiance | $213 | $22,68916 claims |
| Lilly USA, LLCTrulicity | $419 | $19,25015 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $15,36321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.